Recombinant CD19 antibody

Catalog No. ABIN5668221

The Rabbit Chimeric anti-CD19 antibody has been validated for FACS, IHC, IP, IF, Dep and in vivo. It is suitable to detect CD19 in samples from Human.

Quick Overview for Recombinant CD19 antibody (ABIN5668221)

Target: CD19 (CD19 Molecule (CD19))

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Rabbit

Clonality: Chimeric

Conjugate: This CD19 antibody is un-conjugated

Application: Flow Cytometry (FACS), Immunohistochemistry (IHC), Immunoprecipitation (IP), Immunofluorescence (IF), Depletion (Dep), In vivo Studies (in vivo)

Clone: FMC63

Product Details anti-CD19 Antibody

Purpose: Anti-CD19 [FMC63], Rabbit IgG, kappa

Specificity: This antibody is specific for human CD19, a 95 kDa protein expressed in the B-lymphocyte lineage.

Characteristics:

Original Species of Ab: Mouse

Original Format of Ab: IgG2a

Purification: Protein A affinity purified

Immunogen: Human prolymphocytic leukaemia cell line JVM3.

Isotype: IgG kappa

Application Details

Application Notes: FMC63 was used for four years as a CD19 antibody in various labs prior to its original publication. There, it was reported that the antibody percipitates CD19 and inhibits the binding of other CD19 antibodies to it (Zola et al., 1991, PMID: 1725979). FMC63 was used for IF and FACS of peripheral blood mononuclear cells (PBMC) from patients with multiple myeloma (MM) (Szczepek et al., 1997, PMID: 9057669) and receptor for hyaluronan (HA)-mediated motility (RHAMM) expressing malignant B-lineage cells in myeloma (Crainie et al., 1999, PMID: 10029598). FMC63 was used for IHC and IIP of B cells in lymphocyte-filled villi and IIP of jejunal isolated lymphoid follicle, respectively, in small bowel specimens from human patients (Moghaddami et al., 1998, PMID: 9834269). FNC63 was used to induce B cell depletion in vivo (DiLillo et al., 2011, PMID: 21248259). FMC63 has been incorporated into a CD19 scFv- 41BB- CD3ζ fusion protein-encoding lentiviral vector, which was used in combination with a UCART19 cell therapy to cure high-risk CD19+ infant acute lymphoblastic leukemia (< a href="https://www.sciencedirect.com/science/article/pii/S0006497119817871" target="_blank">Qasim et al., 2017). This clone did not compete with clone HD37 (available as Ab00214) (Sakemura et al., 2023, PMID: 37879074).

Comment:

This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques.

Restrictions: For Research Use only

Handling

Concentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Target Details for CD19

Target: CD19 (CD19 Molecule (CD19))

Alternative Name: CD19

Background: B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, Differentiation antigen CD19, Leu12, T-cell surface antigen Leu-12

UniProt: P15391

Pathways: Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway